Search

D-JNKI-1

A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the

NP-50301

NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

EP-2104R

It is being developed by EPIX Pharmaceuticals, Inc. … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.

NPS-2143

[Methyltelluro]Acetate

[methyltelluro]acetate is a solid. This compound belongs to the organic oxoanionic compounds. These are organic compounds containing an oxoanion.

LG-100268

LG-100268 is a retinoid X receptor (RXR) selective compound.

L-756423

Isoluminol

3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone

Triglu-5-formyl-tetrahydrofolate